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Abstract ADP-ribosylation factors (ARFs) regulate coatomer
assembly on the Golgi as well as recruitment of clathrin adapter
proteins and are therefore involved in vesicle budding from the
Golgi and vesicular transport. They are also regulators of
phospholipase D (PLD) activity. Arfaptin 1 is an ARF binding
protein that inhibits PLD activation, vesicular trafficking and
secretion. In the present report, we show that arfaptin 1 interacts
with ‘high speed’ membranes independently of ARF. However,
addition of myristoylated ARF3 (myrARF3) increases the
association of arfaptin 1 with the membranes, suggesting that
arfaptin 1 and ARF form a complex on the Golgi. Utilizing
several deletion mutants of arfaptin 1 it is shown that the
association of arfaptin 1 with myrARF3 is mediated via two
binding sites on arfaptin 1. These two domains are needed for
arfaptin 1 inhibition of PLD activation by myrARF3 in vitro.
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1. Introduction
ADP-ribosylation factors (ARFs) play a key role in COPI
(coatomer) assembly on the Golgi and maintenance of traf-
¢cking through the Golgi [1]. They are also involved in the
recruitment of adapter proteins to membranes for the assem-
bly of clathrin-coated vesicles [2]. Inactivation of ARF by
brefeldin A, an inhibitor of guanine nucleotide exchange on
ARF, abolishes tra⁄cking from the Golgi, secretion and ¢-
nally leads to a collapse of the Golgi into the endoplasmic
reticulum [1]. ARF is also a well established regulator of
phospholipase D (PLD) in vitro [3,4]. PLD hydrolyzes phos-
phatidylcholine to phosphatidic acid and free choline. In the
presence of a primary alcohol, a transphosphatidylation reac-
tion, in which the lipid moiety is transferred to the alcohol
instead of water, takes place [5]. The cloning of the ARF-
dependent PLD1 isozyme and its localization to the Golgi
[6] raised the possibility that PLD1 mediates some of the
e¡ects of ARF in this organelle.
Arfaptin 1 is a 39 kDa class I ARF binding protein that
associates with Golgi upon binding to active guanosine-5P-O-
(3-thiotriphosphate) (GTPQS)-liganded ARF3 [7]. We have re-
cently focused our research on the intracellular role of arfap-
tin 1. It was revealed that in vivo arfaptin 1 inhibits PLD
activity resulting in impaired intracellular tra⁄cking and se-
cretion [8]. While the physiological role of arfaptin 1 is begin-
ning to be understood, little is known about the biochemical
mechanisms behind these e¡ects. Therefore, in the present
study we concentrated on understanding the interaction of
arfaptin 1 with ARF3 and Golgi, and its inhibitory e¡ect
on PLD activation by ARF.
We show here that association of arfaptin 1 with ‘high
speed’ membranes is independent of ARF. However, it is
greater and saturable in the presence of ARF. These data
suggest that ARF and arfaptin 1 participate in formation of
a complex on the Golgi and we propose that another docking
protein may be involved. The mode of interaction of arfaptin
1 with ARF was further studied. Employing seven glutathione
S-transferase (GST) fusion deletion mutants of arfaptin 1 we
identi¢ed two ARF3 binding sites on arfaptin 1, one at amino
acids 64^116 and the other in the last 76 amino acids. We
have previously observed that arfaptin 1 inhibits the stimula-
tion of PLD by ARF [9]. We tested the involvement of the
two ARF binding sites in the inhibition by arfaptin 1 of ARF-
dependent PLD activation, and found that both sites were
needed.
2. Materials and methods
2.1. Materials
All organic solvents were ¢ne grade and obtained from Fisher.
Phosphatidylcholine (PC), phosphatidylethanolamine, phosphatidyl-
inositol 4,5-biphosphate (PIP2), bovine serum albumin (BSA) and
isopropyl L-D-thiogalactopyranoside were purchased from Sigma.
Horseradish peroxidase-labeled horse anti-mouse antibody was from
Vector. Sepharose-glutathione beads, nitrocellulose membranes and
enhanced chemiluminescence reagents were purchased from Amer-
sham. Dithiothreitol (DTT), guanosine-5P-O-(2-thiodiphosphate)
(GDPLS) and GTPQS were purchased from Boehringer Mannheim.
[2-Palmitoyl-9,10-3H]phosphatidylcholine and [35S]GTPQS were prod-
ucts of NEN. Acrylamide:bisacrylamide was purchased from Nation-
al Diagnostics. DNA polymerase and DNA ligase were obtained from
Promega.
2.2. Preparation of GST-fused deletion mutants of arfaptin 1
All mutants were prepared by polymerase chain reaction with
5PBamHI and 3PEcoRI restriction sites. N-terminal deletion mutants
were created using the 3P (antisense) oligonucleotide primer 5P-CCG-
GAATTCTTACTGTTCTTCAAGCCAAGA-3P. For 5P (sense) the
following primers were used: 5P-CGCGGATCCCAAGCACATAAG-
AAAAATAT-3P for arfaptin 1 (266^341), 5P-CGCGGATCCGAGA-
CTCTTCTTGGGGCCATT-3P for arfaptin 1 (197^341), 5P-CGCGG-
ATCCCGTGGCTCAAGAACTGTGGAC-3P for arfaptin 1 (117^
341) and 5P-CGCGGATCCGGAGCATTTCAAGGTGGCCAG-3P
for arfaptin 1 (64^341). The mutant arfaptins comprised amino acids
266^341, 197^341, 117^341 and 64^341, respectively. C-terminal dele-
tion mutants were created using the 5P (sense) oligonucleotide primer
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5P-CGCGGATCCATGGCTCAAGAATC-TCCCAA 5P primer. The
following oligonucleotides were used for 3P (antisense) primers: 5P-
CCGGAATTCACCTTGAAATGCTCCTGCTTC-3P for arfaptin 1
(1^68), 5P-CCGGAATTCCACCAAAGTGTTCACACTAGC-3P for
arfaptin (1^204) and 5P-CCGGAATTCATATTTTTCCTTATGTGC-
TTG-3P for arfaptin (1^272). These mutant arfaptins comprised amino
acids 1^68, 1^204 and 1^272, respectively. The mutants were subcl-
oned into pGEX-4T vector in the BamHI/EcoRI site. The plasmids
were introduced into Escherichia coli (DH5K) and GST fusion pro-
teins were prepared from isopropyl L-D-thiogalactopyranoside-in-
duced bacteria. We were unable to obtain and express mutant for amino
acids 1^120. The sequences of all polymerase chain reaction products
were con¢rmed by the Cancer Center DNA Sequencing Laboratory at
Vanderbilt University.
2.3. Puri¢cation of GST fusion proteins and myrARF3
GST fusion proteins were puri¢ed from transformed E. coli (DH5K)
as described [10], except that before a⁄nity chromatography, the
bacterial lysate was dialyzed against phosphate-bu¡ered saline (PBS)
(2.68 mM KCl, 1.47 mM KH2PO4, 8.05 mM Na2PO4, 137 mM NaCl)
for 24 h at 4‡C. After puri¢cation, all the GST fusion proteins that
were used for binding assays were ¢rst dialyzed against PBS for 24 h
at 4‡C to remove glutathione. Recombinant myristoylated ARF3
(myrARF3) was prepared as previously described [7].
2.4. In vitro PLD assay
In vitro PLD assays were performed using a lysate from COS-7
cells transfected with rat liver PLD1 (rPLD1) as described [11].
GST-arfaptin 1 was ¢rst incubated with myrARF3 and the PLD
preparation in reaction bu¡er for 15 min on ice. Then 1-butanol
and phospholipid vesicle substrate containing [3Hpalmitoyl]phosphati-
dylcholine were added and the reaction allowed to proceed at 37‡C
for 30 min. PLD activity was measured by the formation of
[3H]phosphatidylbutanol.
2.5. Cell fractionation
HT 1080 ¢brosarcoma cells were maintained in DMEM, 10% fetal
calf serum, 10 U/ml penicillin and 10 Wg/ml streptomycin. Before
fractionation, the cells were serum-deprived for 18 h in DMEM,
0.1% BSA. They were then washed with PBS and scraped in fraction-
ation bu¡er (100 mM KCl, 5 mM NaCl, 1 mM MgCl2 and 0.5 mM
EDTA in 50 mM HEPES pH 7.2). The cells were broken by 30 min
cavitation under 350 psi nitrogen and 40 s sonication. Unbroken cells
and large debris were removed by 15 min centrifugation at 750Ug.
The recovered supernatant was centrifuged at 12 600Ug for 20 min to
remove plasma membranes. A ‘high speed’ membrane fraction was
separated from the cytosol by a ¢nal centrifugation at 38 600Ug for
75 min and resuspended in fractionation bu¡er. The supernatant was
used as a source for cytosol.
2.6. ARF3 loading with GTPQS and binding assay
Loading myrARF3 with [35S]GTPQS was carried out by incubating
1.3 WM ARF3 in loading bu¡er (25 mM HEPES pH 7.4, 100 mM
NaCl, 25 mM KCl, 1 mM DTT, 1 mM EDTA, 0.1% Triton X-100,
2.5 mM MgCl2, 0.3 mg/ml BSA) containing 6.25 mg/ml PC and 10 WM
[35S]GTPQS (4 WCi/nmol). After 30 min at 37‡C, MgCl2 was added to
a ¢nal concentration of 15 mM. For binding assays 0.9 WM GSTfu-
sion proteins in a ¢nal volume of 500 Wl were immobilized on gluta-
thione-Sepharose by 1 h incubation at room temperature in PBS con-
taining 60 mg/ml BSA. Following washing with bu¡er (25 mM Tris
pH 8.0, 100 mM NaCl, 10 mM MgCl2, 1 mM DTT) the beads were
incubated with 1.3 WM [35S]GTPQS-loaded myrARF3 for 1 h at room
temperature, unless otherwise described. The beads were then washed
with the same bu¡er and radioactivity associated with the beads was
measured by scintillation spectroscopy.
3. Results
3.1. ARF and arfaptin 1 form a complex on ‘high speed’
membranes
Arfaptin 1 has previously been shown to associate with the
GTPQS-bound form of ARF1 and interact with Golgi mem-
branes [7]. In the present study, the association of arfaptin 1
with ‘high speed’ membranes of HT 1080 cells was studied.
GST-arfaptin 1 was incubated with this membrane fraction in
the absence and presence of cytosol (as a source of ARF).
Surprisingly, a signi¢cant amount of GST-arfaptin 1 associ-
ated with the membranes in the absence of cytosol, suggesting
that arfaptin 1 interacts with the membranes independently of
added ARF (Fig. 1A). In contrast, arfaptin 1 did not associate
with plasma membrane preparations from these cells (data not
shown). To investigate whether the association was due to
ARF and Golgi present in the membrane preparations, the
translocation of GST-arfaptin 1 to the membranes was as-
sayed in the absence of cytosol and with GTPQS or GDPLS
(Fig. 1B). The nucleotides were included because arfaptin 1
only binds ARF when it is in the GTPQS (or GTP)-liganded
form [7]. The ¢gure shows that the association of GST-arfap-
tin 1 with the membranes was not abolished when GDPLS
was added to the reaction, illustrating that arfaptin 1 is capa-
ble of interacting with the membranes independently of ARF.
However, the association of arfaptin 1 was greater in the
presence of GTPQS indicating an additional role for ARF,
as shown previously [7].
Further evidence for the involvement of ARF in the asso-
ciation of arfaptin 1 with the membranes from an experiment
in which they were incubated with a constant amount of GST-
Fig. 1. Interaction of arfaptin 1 with ‘high speed’ membranes from
HT 1080 cells. A: Translocation of 25 and 50 ng GST-arfaptin 1
was assayed with 20 Wg ‘high speed’ membranes in the absence or
presence of 20 Wg cytosol. The translocation bu¡er contained 20 WM
GTPQS. Association with the membranes after 45 min incubation at
37‡C was assayed by immunoblotting the membranes with mouse
anti-GST antibody and then horseradish peroxidase-labeled horse
anti-mouse antibody and utilizing enhanced chemiluminescence. The
position of a GST-arfaptin 1 standard is shown by the arrow. B:
Association of 20 ng GST-arfaptin 1 with 20 Wg ‘high speed’ mem-
brane fraction was measured with 20 WM GTPQS or GDPLS. C:
The translocation assay was repeated with 20 ng GST-arfaptin 1, 40
ng GST-ARF3, 20 Wg Golgi, 20 Wg cytosol and the indicated
amounts of myrARF3.
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arfaptin 1 and increasing concentrations of myristoylated
ARF3 (myrARF3) in the presence of GTPQS and cytosol
(Fig. 1C). GST-arfaptin 1 associated with the membranes in
the absence of ARF, however the addition of myrARF3 dose-
dependently increased the amount of arfaptin 1 present.
3.2. Association of ARF3 with arfaptin 1 is mediated through
two sites on arfaptin 1
The association of ARF3 with arfaptin 1 was further char-
acterized. We ¢rst de¢ned the interaction of GST-arfaptin 1
with ARF and then used deletion mutants of arfaptin 1 to
localize the ARF binding sites on arfaptin 1. myrARF3 was
loaded with [35S]GTPQS and then diluted to various concen-
trations that were allowed to interact with glutathione-immo-
bilized GST-arfaptin 1. After incubation for 1 h, free myr-
ARF and excess GTPQS were washed from the beads and
the association of arfaptin 1 with myrARF3 was measured
by the radioactivity associated with the beads. As shown in
Fig. 2, the association of myrARF with arfaptin 1 was con-
centration-dependent and largely monophasic.
In order to identify the ARF binding site(s) of arfaptin 1 we
prepared seven deletion mutants of arfaptin 1 fused to GST at
its N-terminus or C-terminus. The mutants were subcloned
into pGEX-4T vector in the BamHI/EcoRI site. The various
mutants are detailed in Fig. 3A. They were used to identify
myrARF3 binding sites on arfaptin 1 by immobilizing them
on Sepharose-glutathione and incubating with [35S]GTPQS-
loaded myrARF3. Fig. 3B illustrates that arfaptin 1 (1^68)
possessed no binding site for ARF since the background bind-
ing to GST alone was 0.2 relative to full length arfaptin 1
fused to GST. Consistent with this, arfaptin 1 (64^341)
showed full binding. However, full binding of ARF could
not be attributed to a single site since all the other mutants
showed partial binding. One binding site was localized to
residues 266^341 at the C-terminus since arfaptin 1 (266^
341) showed binding, as did arfaptins 1 (197^341), (117^341)
and (64^341). On the other hand arfaptin 1 (1^204) and (1^
172) which lack the C-terminal site also showed binding. The
second site was localized to residues 64^116. This was because
arfaptin 1 (64^341) showed full binding whereas arfaptin 1
(117^341) showed only partial binding. In summary, the ¢nd-
ings with all the mutants supported the existence of two bind-
ing sites, in the 64^116 and 266^341 amino acid sequences.
Fig. 2. Association of ARF3 with arfaptin 1. Interaction of arfaptin
1 with ARF was assayed with various concentrations of myrARF3.
GST-arfaptin 1 was immobilized on Sepharose-glutathione by incu-
bating 0.5 ml of 0.9 WM GST-arfaptin 1 in PBS, 60 mg/ml BSA for
1 h at room temperature. ARF3 was loaded with [35S]GTPQS by in-
cubating 1.3 WM myrARF3 with 10 WM [35S]GTPQS (4 WCi/nmol) in
loading bu¡er containing PC for 30 min at 37‡C after which MgCl2
was added to a ¢nal concentration of 15 mM. ARF3 was diluted in
loading bu¡er to the indicated concentrations and incubated with
the immobilized GST-arfaptin 1 for 1 h at room temperature. The
beads were washed with wash bu¡er and binding was measured by
the radioactivity associated with the immobilized arfaptin 1. Data
are expressed as the mean of fold binding of three independent ex-
periments performed in duplicate þ S.E.M.
Fig. 3. The association of arfaptin 1 with ARF3 is mediated
through two ARF3 binding sites on arfaptin 1. A: Seven deletion
mutants of arfaptin 1 were prepared as described in Section 2. B:
Full length 0.9 WM GST-arfaptin 1 and its deletion mutants were
immobilized on Sepharose-glutathione and then allowed to interact
with 1.3 WM [35S]GTPQS-loaded myrARF3. After 1 h at room tem-
perature and removing excess mARF3 by extensive washing with
wash bu¡er, the radioactivity associated with the beads was meas-
ured by scintillation spectrometry. Data are expressed as the mean
of fold binding in comparison to full length arfaptin 1 in six inde-
pendent experiments performed in duplicate þ S.E.M.
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3.3. Inhibition of PDL activity by arfaptin 1 deletion mutants
ARF proteins are a well established regulators of PLD
[2,3,12^15]. Overexpression of arfaptin 1 has been shown to
decrease PLD-activation in PMA-stimulated HT 1080 cells
(B.-T. Williger, W.-T. Ho and J.H. Exton, submitted for pub-
lication) and NIH 3T3 cells [8]. Arfaptin 1 has also been
reported to inhibit the e¡ect of several ARF isoforms on
PLD partially puri¢ed from bovine brain [9]. We therefore
tested whether the inhibitory of arfaptin 1 on PLD required
one or both ARF binding sites. Fig. 4A illustrates that arfap-
tin 1 caused a concentration-dependent inhibition of the e¡ect
of myrARF3 on PLD activity in lysates from COS-7 cells
overexpressing rPLD1. Next we assayed the inhibitory e¡ect
of the arfaptin 1 deletion mutants on the stimulation of
rPLD1 by myrARF3. The data of Fig. 4B shows clearly
that, of all the mutants, only arfaptin 1 (64^341) that con-
tained both binding sites was able to inhibit the e¡ect of ARF
on the enzyme. All the other mutants, which contained only
one ARF binding site, were completely without e¡ect.
4. Discussion
ARF is an important regulator of Golgi functions, but the
mechanisms regulating ARF or its e¡ects are poorly under-
stood. ARF interacts with Golgi mainly when it is in its GTP-
bound form [1], making its exchange factors and GTPase
activators important regulators by governing its activation
status. Myristoylation may also play a role in regulation of
ARF association with the Golgi. The cloning of arfaptin 1,
and ARF binding protein [7], provided another potential reg-
ulator of ARF e¡ects and of the secretory pathway. We show
here that arfaptin 1 forms a complex with ARF3 in ‘high
speed’ membranes and the arfaptin 1 interacts with ARF3
through two distinct sites. Upon interaction with ARF
through both of the binding sites, arfaptin 1 inhibits PLD
activity.
Arfaptin 1 was observed to associate with the ‘high speed’
membrane fraction to a greater extent in the presence of myr-
ARF3. The binding was saturable in that increasing myr-
ARF3 from 100 to 200 ng did not cause further arfaptin 1
binding. Nevertheless, some membrane binding was still evi-
dent in the absence of myrARF3 and was not abolished by
GDPLS, which inhibits the interaction of arfaptin 1 with
ARF. We propose that the interaction or arfaptin 1 with
the ‘high speed’ membranes involves Golgi membranes. We
believe that this is the case because of the enhancement of the
association by myrARF3, which is known to be localized to
Golgi membranes [16]. The limited ARF-independent interac-
tion of arfaptin 1 with the membranes is in agreement with
the low presence in highly puri¢ed Golgi membranes from rat
liver (Fig. 6 and 7 in [7]). These latter results suggest a direct,
ARF-independent, interaction of arfaptin 1 with the Golgi.
Therefore, it seems possible that arfaptin 1 forms, together
with ARF, a complex on the Golgi by interacting with an
unknown docking protein. However, overexpression of arfap-
tin 1 results in inhibition of vesicular tra⁄cking involving the
Golgi [8].
To determine the site(s) at which ARF bound to arfaptin 1,
we examined the interaction of various arfaptin 1 mutants
with ARF3. Analysis of the various mutants revealed the
presence of one ARF binding site between amino acids 64^
116, and another between amino acids 266^341. The existence
of two binding sites is supported by the signi¢cantly higher
binding of arfaptin 1 (64^341), which was the only mutant
that contained both binding sites. This mutant bound ARF3
to the same extent as wild type arfaptin 1. Interestingly, this
mutant was the only one which fully inhibited the activation
of rPLD1 by ARF3, suggesting that interaction with ARF3
through both of its binding sites is needed for arfaptin 1 to
fully inhibit PLD1 activity. Since studies with puri¢ed pro-
Fig. 4. GST-arfaptin 1 inhibits ARF3-dependent PLD1 activation
only in the presence of the two ARF3 binding sites. rPLD1-enriched
membrane preparations from COS-7 cells (5 Wg/reaction), 3 WM
myrARF3 were incubated with (A) various concentrations of GST-
arfaptin 1 or (B) 0.9 WM of each GST-fused deletion mutant of ar-
faptin 1, for 15 min on ice to allow interaction of the various com-
ponents. A mixture containing PE/PIP2/[3H]PC (16:1.4:1) and 1-bu-
tanol (¢nal concentration of 0.3%) was added and the reaction
mixture was incubated for 30 min at 37‡C. PLD activity was deter-
mined by the formation of [3H]PtdBut. Data presented are represen-
tative of three independent experiments performed in triplicate þ
S.E.M.
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teins have indicated that ARF interacts directly with PLD
[14,15], it is likely that arfaptin 1 interferes with that interac-
tion and prevents the activation of PLD by ARF3.
Tsai et al. [9] have recently shown that the ¢rst 13 N-ter-
minal amino acids of ARF are essential for arfaptin 1 inhibi-
tion of its activation of cholera toxin ADP-ribosyltransferase.
The same sequence has been implicated in the activation of
PLD by ARF [9]. This suggests that arfaptin 1 binds to the N-
terminus of ARF and thus blocks its interaction with PLD.
An important issue is whether or not the activity of arfaptin 1
is regulated in the cell through phosphorylation or another
mechanism. Interestingly, protein kinase C has been reported
to phosphorylate arfaptin 1 [7], but it is not known if this
alters its activity.
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